Online citations, reference lists, and bibliographies.
← Back to Search

A Clinical, Radiographic And Laboratory Evaluation Of Prognostic Factors In 363 Patients With Malignant Pleural Mesothelioma

A. C. Tanrıkulu, A. Abakay, M. A. Kaplan, M. Küçüköner, Y. Palancı, O. Evliyaoğlu, C. Sezgi, H. Şen, Ali İhsan Çarkanat, G. Kirbas
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background: Malignant pleural mesothelioma (MPM) has a poor prognosis. Objectives: Only few studies in literature investigated the presence of pleural fluid and radiographic findings for the prognosis of MPM. Methods: We retrospectively investigated the hospital charts of 363 MPM patients who were diagnosed from January 1989 to March 2010. Survival time was calculated by the Kaplan-Meier method. Pretreatment clinical, laboratory and radiographic features of each patient at the time of diagnosis were obtained from patients’ charts. Results: The mean age of 363 patients (217 men, 146 women) was 50.6 ± 11.2 years (range 19–85) and the mean survival time was 11.7 ± 8.6 months (range 1–53). Histological types of MPM were epithelial (71.2%), mixed (15.9%) and sarcomatous type (4.9%). The frequency of disease stages were 31.4% for stage 1, 24.2% for stage 2, 28.6% for stage 3 and 15.8% for stage 4. The most frequent symptoms were dyspnea (82.1%), chest pain (68.3%) and weight loss (58.9%). Results of univariate and multivariate analyses revealed that a Karnofsky performance score ≤60, a pleural fluid glucose level ≤40 mg/dl, a C-reactive protein level >50 mg/l, a serum lactate dehydrogenase level >500 U/l, the presence of pleural fluid, pleural thickening >1 cm and a platelet count of >420 × 103/µl were found to be associated with poor prognosis in MPM. Conclusions: Our data suggest that low pleural fluid glucose and high C-reactive protein, the presence of pleural fluid and pleural thickening were associated with poor MPM prognosis. Further prospective studies are needed to highlight prognostic factors more clearly.
This paper references
10.1016/J.LUNGCAN.2004.04.012
Prognostic factors in malignant mesothelioma.
J. Burgers (2004)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
10.1159/000127577
Mesothelioma and Asbestos-Related Pleural Diseases
L. Greillier (2008)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1159/000165054
Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
S. Wilop (2008)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.2214/AJR.155.5.2120965
Malignant pleural mesothelioma: CT manifestations in 50 cases.
A. Kawashima (1990)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1002/1097-0142(19930715)72:2<410::aid-cncr2820720216>3.0.co;2-g
Prognostic factors of malignant mesothelioma of the pleura
V. de Pangher Manzini (1993)
vival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register , 1988 – 2000 : a population - based study
G Gorini (2005)
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
10.1186/1750-1172-3-34
Malignant mesothelioma
A. Moore (2008)
10.1164/AJRCCM.158.6.9712119
Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage.
P. Dumortier (1998)
Malignant mesotheliomas diagnosed in Lower Normandy
M Letourneux (1980)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
Environmental malignant pleural mesothelioma in Southeast Turkey.
A. C. Tanrıkulu (2006)
10.1097/JTO.0b013e31819578c8
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy
A. Koch (2009)
10.1002/jcla.20266
Pleural fluid findings as prognostic factors for malignant pleural mesothelioma
T. Gonlugur (2008)
10.1080/14774003.2005.11667666
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
10.1378/CHEST.100.4.1003
Pleural fluid analysis in malignant mesothelioma. Prognostic implications.
A. Gottehrer (1991)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1097/00008469-200506000-00001
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study
G. Gorini (2005)
10.1016/0169-5002(93)90470-i
Malignant mesothelioma: diagnostic and management strategies for 1992.
N. Vogelzang (1992)
10.5694/j.1326-5377.1993.tb141344.x
A population based study
P. McIntyre (1993)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
10.1378/CHEST.102.3.790
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.1016/j.amjcard.2008.04.026
Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome.
Russell Stein (2008)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
Malignant mesotheliomas diagnosed in Lower Normandy between 1980 and 1990
M Letourneux (1993)
10.1159/000056290
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1016/S0169-5002(00)00249-X
Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma.
S. Emri (2001)
Preoperative serum C-reactive protein level in non-small cell lung cancer.
M. Hara (2007)
10.1053/RMED.2001.1178
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma.
B. Baris (1996)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/S0344-0338(11)81020-4
Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
R. Walz (1990)



This paper is referenced by
10.5301/tj.5000418
Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma
R. Berardi (2016)
10.4149/neo_2014_053
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
H. Kaya (2014)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.3390/cancers12113470
DNA Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma
G. Cugliari (2020)
10.7314/APJCP.2013.14.1.249
Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.
G. Utkan (2013)
10.1016/j.crad.2019.12.001
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
S. Sinha (2020)
10.1183/13993003.00501-2020
PLEASE, take a deep breath
J. M. Porcel (2020)
10.1097/FPC.0b013e32834e3572
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma
N. Erčulj (2012)
10.1007/s13665-016-0133-0
Nutrition, exercise, and complementary medicine: potential role in mesothelioma?
S. Muruganandan (2016)
10.1007/s00432-013-1523-0
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma
Zhou-Hong Yao (2013)
10.1101/2020.10.22.350850
KRAS signalling in malignant pleural mesothelioma
A. Marazioti (2020)
10.15761/ICST.1000163
Systemic inflammation in malignant pleural mesothelioma: Is neutrophyl-to-lymphocyte ratio a prognostic index?
Felice Mucilli (2016)
10.1097/JTO.0000000000000181
Supplementary Prognostic Variables for Pleural Mesothelioma
H. Pass (2014)
10.1016/j.cllc.2012.03.011
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
10.5798/DICLEMEDJ.0921.2013.02.0262
Malign Plevral Mezotelyoma prognozunda yeni bir inflamatuar parametrenin değeri
Çetin Tanrıkulu (2013)
10.1007/978-1-4939-2374-8_3
Clinical and Radiologic Features
A. Roden (2015)
10.1007/s12199-016-0530-6
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
A. C. Tanrıkulu (2016)
10.1016/j.compbiolchem.2015.09.012
Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma
V. Tasiopoulou (2015)
10.3978/j.issn.2225-319X.2012.10.02
Inflammation in malignant mesothelioma - friend or foe?
Anthony Linton (2012)
10.5761/atcs.cr.13-00086
Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.
K. Matsuoka (2014)
10.7314/APJCP.2015.16.4.1403
Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
H. Kaya (2015)
10.4103/0973-1482.138094
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
A. Koyuncu (2015)
10.4081/CDR.2011.E13
Asbestos-the Silent Killer: a review of screening and diagnostic imaging of asbestos related lung disease
Ali Khan (2011)
10.1002/ccr3.371
Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema
K. Fujita (2015)
10.1097/JTO.0b013e3182653d31
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy
N. Erčulj (2012)
10.1097/SLA.0b013e3182602af4
Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma: A Retrospective Multicenter Analysis
B. Ghanim (2012)
10.1007/s12199-015-0501-3
High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos
A. Abakay (2015)
10.1513/AnnalsATS.201811-786OC
The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.
A. Bibby (2019)
10.1038/s41467-018-03051-z
Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
A. Marazioti (2018)
10.1111/j.1759-7714.2012.00127.x
Clinical and biologic prognostic factors in malignant pleural mesothelioma
V. Ambrogi (2012)
10.1093/jjco/hyv039
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Yuki Kataoka (2015)
Malignant pleural mesothelioma: factors influencing the prognosis.
T. Mineo (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar